Abstract 115P
Background
Colorectal cancer is in fourth place due to mortality worldwide. In order to improve the diagnosis of colorectal cancer, immunohistochemical studies are becoming increasingly popular. The available literature contains a number of publications devoted to the study of the prognostic value of the expression of various biomarkers. However, the value of expression levels of the proliferation marker Ki-67 in colorectal cancer remains poorly understood. In this regard, the purpose of our study was to study the clinical significance of the expression of Ki-67 as a prognostic factor in patients with colorectal cancer.
Methods
To study the clinical significance of the expression of Ki-67 as a prognostic factor in patients with colorectal cancer, we examined 201 patients with colorectal cancer who were undergoing surgical treatment in combination with chemotherapy.
Results
A study of the proliferative activity of tumor glandular epithelial cells using patient Ki-67 proliferation marker showed that low or medium expression level (≤ 30%) was observed in 138 (68.9%) patients, while high (> 30%) - in 63 patients (31.1%). Binary logistic regression made it possible to establish links between the expression level of Ki-67 and the tumor stage, the presence of metastases in regional lymph nodes, the presence of distant metastases and the degree of tumor differentiation. In particular, patients with stage II, III, and IV stages of cancer had a higher chance of having a high level of Ki-67 expression than patients with stage I disease — 2.63, 3.16, and 3.97 times, respectively. The presence of 4 or more regional lymph nodes (N2) was accompanied by higher chances (6.6 times) to have a high level of expression of Ki-67, and the presence of distant metastases (M1) - by 1.92 times. Patients with low-differentiated cancer had a 5.1- times higher chance of being in the group with a high level of Ki-67 expression than patients with highly differentiated cancer.
Conclusions
The results of the research on finding the most informative and effective methods for predicting and diagnosing colorectal cancer among residents of the studied region will allow developing and introducing methods for complex primary and secondary prevention.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
329P - High-level expression of HDAC10 is associated with PD-L1 expression and poor prognosis in patients with non-small cell lung cancer receiving pulmonectomy
Presenter: Xiaomei Liu
Session: Poster display session
Resources:
Abstract
331P - A retrospective analysis of immune checkpoint therapy in patients with non-small cell lung cancer: Focus on thyroid disorder
Presenter: Sawana Ono
Session: Poster display session
Resources:
Abstract
332P - Analyse the association between adverse events (AEs) and survival in patients treated with immune checkpoint inhibitors (ICIs)
Presenter: Chi-yuan Cheng
Session: Poster display session
Resources:
Abstract
333P - Study of searching on efficacy of immune checkpoint inhibitor for the non-small cell lung cancer using FDG-PET/CT and thallium SPECT
Presenter: KAYOKO Kibata
Session: Poster display session
Resources:
Abstract
334P - Incidence and characteristic of adrenal insufficiency due to immune checkpoint inhibitors therapy
Presenter: Daisuke Etoh
Session: Poster display session
Resources:
Abstract
335P - PD-L1 profile of nasopharyngeal cancer patients in Indonesia
Presenter: Handoko Handoko
Session: Poster display session
Resources:
Abstract
336P - Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world
Presenter: Jun Sugisaka
Session: Poster display session
Resources:
Abstract
337P - Neutrophil-to-Lymphocyte ratio as a predictive factor for hyperprogressive disease in NSCLC patients treated with immune checkpoint inhibitor
Presenter: Ryo Takahashi
Session: Poster display session
Resources:
Abstract
338P - A new insight into tumour immune-evasion: Crosstalk between cancer stem cells and T regulatory cells
Presenter: Abhishek Dutta
Session: Poster display session
Resources:
Abstract
339TiP - PACIFIC-5: Phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract